Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.22
HCM's Cash-to-Debt is ranked lower than
52% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. HCM: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
HCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 1.82 Max: 9.93
Current: 2.22
0.64
9.93
Equity-to-Asset 0.55
HCM's Equity-to-Asset is ranked lower than
59% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. HCM: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
HCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54  Med: 0.46 Max: 0.77
Current: 0.55
-0.54
0.77
Piotroski F-Score: 6
Altman Z-Score: 8.81
WACC vs ROIC
16.29%
-51.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 129.69
HCM's Operating Margin % is ranked lower than
78% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.86 vs. HCM: 129.69 )
Ranked among companies with meaningful Operating Margin % only.
HCM' s Operating Margin % Range Over the Past 10 Years
Min: -21.61  Med: -4.82 Max: 129.69
Current: 129.69
-21.61
129.69
Net Margin % 211.47
HCM's Net Margin % is ranked lower than
59% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. HCM: 211.47 )
Ranked among companies with meaningful Net Margin % only.
HCM' s Net Margin % Range Over the Past 10 Years
Min: -26.4  Med: -2.34 Max: 211.47
Current: 211.47
-26.4
211.47
ROE % -135.87
HCM's ROE % is ranked lower than
80% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. HCM: -135.87 )
Ranked among companies with meaningful ROE % only.
HCM' s ROE % Range Over the Past 10 Years
Min: -135.87  Med: -11.5 Max: 9.22
Current: -135.87
-135.87
9.22
ROA % -49.38
HCM's ROA % is ranked lower than
55% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.48 vs. HCM: -49.38 )
Ranked among companies with meaningful ROA % only.
HCM' s ROA % Range Over the Past 10 Years
Min: -49.38  Med: -1.69 Max: 4.38
Current: -49.38
-49.38
4.38
ROC (Joel Greenblatt) % -819.14
HCM's ROC (Joel Greenblatt) % is ranked lower than
85% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.44 vs. HCM: -819.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -819.14  Med: -17.31 Max: 193.62
Current: -819.14
-819.14
193.62
3-Year Revenue Growth Rate 75.90
HCM's 3-Year Revenue Growth Rate is ranked higher than
97% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. HCM: 75.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.8  Med: 24.5 Max: 100.1
Current: 75.9
-41.8
100.1
3-Year EPS without NRI Growth Rate 23.60
HCM's 3-Year EPS without NRI Growth Rate is ranked higher than
73% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. HCM: 23.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -10  Med: 17.85 Max: 30.1
Current: 23.6
-10
30.1
GuruFocus has detected 3 Warning Signs with Hutchison China Meditech Ltd $HCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HCM's 10-Y Financials

Financials (Next Earnings Date: 2017-06-13 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with HCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NAS:AERI, OTCPK:MAYNF, NAS:GWPH, AMEX:TXMD, OTCPK:VEGPF, NAS:RTRX, NAS:ASMB, NAS:NBRV, NAS:RMTI, NAS:ZGNX, NAS:ALIM, OTCPK:FAMDF, OTCPK:BIOYF, AMEX:NNVC, NAS:OASM, NAS:PRPH, AMEX:AXN, NAS:NVGN, NAS:IMNP, OTCPK:SUWN » details
Traded in other countries:H7T.Germany, HCM.UK, HNCMF.USA,
Hutchison China Meditech Ltd and its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. It also market and sell organic and natural consumer products in Asia.

Hutchison China Meditech Ltd is a biopharmaceutical company incorporated in the Cayman Islands on December 18, 2000. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. The Company's clinical-stage drug candidates includes Savolitinib a potential inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors; Fruquintinib a selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR; Sulfatinib an oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth factor receptor 1, or FGFR1, a receptor for a protein which also plays a role in tumor growth; HMPL-523 a potential oral inhibitor targeting the spleen tyrosine kinase, or Syk, a key protein involved in B-cell signaling; Epidermal growth factor receptor, or EGFR, inhibitors have revolutionized the treatment of non-small cell lung cancer with EGFR activating mutations; and theliatinib is a potent and selective oral EGFR inhibitor engineered to have greater binding affinity to wild-type EGFR proteins. The Company faces competition from different sources, including pharmaceutical, specialty pharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
PB Ratio 12.04
HCM's PB Ratio is ranked lower than
91% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.93 vs. HCM: 12.04 )
Ranked among companies with meaningful PB Ratio only.
HCM' s PB Ratio Range Over the Past 10 Years
Min: 8.65  Med: 9.06 Max: 12.59
Current: 12.04
8.65
12.59
PS Ratio 50.99
HCM's PS Ratio is ranked lower than
92% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. HCM: 50.99 )
Ranked among companies with meaningful PS Ratio only.
HCM' s PS Ratio Range Over the Past 10 Years
Min: 10.46  Med: 11.11 Max: 53.31
Current: 50.99
10.46
53.31
Price-to-Free-Cash-Flow 375.31
HCM's Price-to-Free-Cash-Flow is ranked lower than
96% of the 228 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.42 vs. HCM: 375.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HCM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 269.87  Med: 290.13 Max: 392.31
Current: 375.31
269.87
392.31
Price-to-Operating-Cash-Flow 348.48
HCM's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.18 vs. HCM: 348.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 250.6  Med: 269.4 Max: 364.29
Current: 348.48
250.6
364.29
EV-to-EBIT -30.57
HCM's EV-to-EBIT is ranked lower than
99.99% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. HCM: -30.57 )
Ranked among companies with meaningful EV-to-EBIT only.
HCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -101.7  Med: -19.1 Max: -17.9
Current: -30.57
-101.7
-17.9
EV-to-EBITDA -23.93
HCM's EV-to-EBITDA is ranked lower than
99.99% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.30 vs. HCM: -23.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
HCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -109.1  Med: -14.9 Max: -14
Current: -23.93
-109.1
-14
Current Ratio 1.76
HCM's Current Ratio is ranked lower than
64% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. HCM: 1.76 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.59 Max: 4.28
Current: 1.76
0.33
4.28
Quick Ratio 1.62
HCM's Quick Ratio is ranked lower than
54% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.73 vs. HCM: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.24 Max: 3.87
Current: 1.62
0.23
3.87
Days Inventory 46.67
HCM's Days Inventory is ranked higher than
92% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. HCM: 46.67 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 17.86  Med: 127.27 Max: 448.99
Current: 46.67
17.86
448.99
Days Payable 170.52
HCM's Days Payable is ranked higher than
69% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. HCM: 170.52 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 53.45  Med: 69.98 Max: 170.52
Current: 170.52
53.45
170.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
HCM's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. HCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.5 Max: 0
Current: -5.3
-11.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 233.88
HCM's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. HCM: 233.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.87  Med: 7.69 Max: 253.34
Current: 233.88
0.87
253.34
Price-to-Tangible-Book 12.31
HCM's Price-to-Tangible-Book is ranked lower than
87% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. HCM: 12.31 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.45  Med: 5.99 Max: 33.29
Current: 12.31
0.45
33.29
Price-to-Intrinsic-Value-Projected-FCF 69.30
HCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. HCM: 69.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 32.67 Max: 71.11
Current: 69.3
0
71.11
Price-to-Median-PS-Value 4.59
HCM's Price-to-Median-PS-Value is ranked lower than
92% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. HCM: 4.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.8 Max: 4.77
Current: 4.59
0.12
4.77
Earnings Yield (Greenblatt) % -3.28
HCM's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. HCM: -3.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.28  Med: 29.2 Max: 30.6
Current: -3.28
-3.28
30.6

More Statistics

EPS (TTM) $ 0.97
Short Percentage of Float0.01%
52-Week Range $9.80 - 21.77
Shares Outstanding (Mil)121.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 218 282 355
EPS ($) -0.04 -0.16 0.43
EPS without NRI ($) -0.04 -0.16 0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HCM

Headlines

Articles On GuruFocus.com

More From Other Websites
Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors Mar 24 2017
Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors Mar 24 2017
Chi-Med To Host R&D Briefings on March 29 & 30, 2017 Mar 21 2017
Chi-Med To Host R&D Briefings on March 29 & 30, 2017 Mar 21 2017
Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016... Mar 17 2017
HUTCHISON CHINA MEDITECH LTD Financials Mar 16 2017
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual... Mar 16 2017
Chi-Med: Grant of Awards under Long Term Incentive Plan Mar 16 2017
Chi-Med: Grant of Awards under Long Term Incentive Plan Mar 16 2017
Chi-Med: Grant of Awards under Long Term Incentive Plan Mar 16 2017
Publication of Annual Report and Financial Results for the Year Ended December 31, 2016 Mar 15 2017
Publication of Annual Report and Financial Results for the Year Ended December 31, 2016 Mar 15 2017
Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS Mar 10 2017
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference... Mar 10 2017
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference... Mar 10 2017
Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market Mar 03 2017
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of... Mar 03 2017
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of... Mar 03 2017
Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results Mar 03 2017
Hutchison China Meditech Limited: Change of Directors Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)